Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study. / Laursen, Peter Nørkjær; Holmvang, Lene; Lønborg, Jacob; Køber, Lars; Høfsten, Dan E; Helqvist, Steffen; Clemmensen, Peter; Kelbæk, Henning; Jørgensen, Erik; Lassen, Jens Flensted; Pedersen, Frants; Høi-Hansen, Thomas; Therkelsen, Christian Juhl; Tilsted, Hans-Henrik; Jensen, Lisette Okkels; Nepper-Christensen, Lars; Sadjadieh, Golnaz; Engstrøm, Thomas.
I: American Heart Journal, Bind 204, 2018, s. 128-138.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Comparison between patients included in randomized controlled trials of ischemic heart disease and real-world data. A nationwide study
AU - Laursen, Peter Nørkjær
AU - Holmvang, Lene
AU - Lønborg, Jacob
AU - Køber, Lars
AU - Høfsten, Dan E
AU - Helqvist, Steffen
AU - Clemmensen, Peter
AU - Kelbæk, Henning
AU - Jørgensen, Erik
AU - Lassen, Jens Flensted
AU - Pedersen, Frants
AU - Høi-Hansen, Thomas
AU - Therkelsen, Christian Juhl
AU - Tilsted, Hans-Henrik
AU - Jensen, Lisette Okkels
AU - Nepper-Christensen, Lars
AU - Sadjadieh, Golnaz
AU - Engstrøm, Thomas
N1 - Copyright © 2018. Published by Elsevier Inc.
PY - 2018
Y1 - 2018
N2 - BACKGROUND: The objective was to compare patients with ischemic heart disease (IHD) undergoing percutaneous coronary intervention (PCI) who were included in randomized controlled trials (RCTs) (trial participants) with patients who were not included (nonparticipants) on a trial-by-trial basis and according to indication for PCI.METHODS: In this cohort study, we compared patients with IHD who were randomized in RCTs in relation to undergoing PCI in Denmark between 2011 and 2015 were considered as RCT-participants in this study. The RCT-participants were compared with contemporary nonparticipants with IHD undergoing PCI in the same period, and they were identified using unselected national registry data. The primary end point was all-cause mortality.RESULTS: A total of 10,317 (30%) patients were included in 10 relevant RCTs (trial participants), and a total of 23,644 (70%) contemporary patients did not participate (nonparticipants). In all the included RCTs, nonparticipants had higher hazard ratios for mortality compared to trial participants (P < .001). Among all patients treated with PCI, the pooled estimates showed a significantly higher mortality rate for nonparticipants compared to trial participants (hazard ratio: 2.03, 95% CI: 1.88-2.19) (P < .001). When patients were stratified according to indication for PCI, the pooled estimates showed a significantly lower mortality rate for trial participants compared to nonparticipants in all strata (P for all < .001).CONCLUSIONS: Trial participants in recently performed RCTs including patients undergoing PCI were not representative of the general population of patients with IHD treated with PCI according to clinical characteristics and mortality. The difference in mortality was found irrespective of the indication for PCI. Thus, results from RCTs including patients undergoing PCI should be extrapolated with caution to the general patient population.
AB - BACKGROUND: The objective was to compare patients with ischemic heart disease (IHD) undergoing percutaneous coronary intervention (PCI) who were included in randomized controlled trials (RCTs) (trial participants) with patients who were not included (nonparticipants) on a trial-by-trial basis and according to indication for PCI.METHODS: In this cohort study, we compared patients with IHD who were randomized in RCTs in relation to undergoing PCI in Denmark between 2011 and 2015 were considered as RCT-participants in this study. The RCT-participants were compared with contemporary nonparticipants with IHD undergoing PCI in the same period, and they were identified using unselected national registry data. The primary end point was all-cause mortality.RESULTS: A total of 10,317 (30%) patients were included in 10 relevant RCTs (trial participants), and a total of 23,644 (70%) contemporary patients did not participate (nonparticipants). In all the included RCTs, nonparticipants had higher hazard ratios for mortality compared to trial participants (P < .001). Among all patients treated with PCI, the pooled estimates showed a significantly higher mortality rate for nonparticipants compared to trial participants (hazard ratio: 2.03, 95% CI: 1.88-2.19) (P < .001). When patients were stratified according to indication for PCI, the pooled estimates showed a significantly lower mortality rate for trial participants compared to nonparticipants in all strata (P for all < .001).CONCLUSIONS: Trial participants in recently performed RCTs including patients undergoing PCI were not representative of the general population of patients with IHD treated with PCI according to clinical characteristics and mortality. The difference in mortality was found irrespective of the indication for PCI. Thus, results from RCTs including patients undergoing PCI should be extrapolated with caution to the general patient population.
U2 - 10.1016/j.ahj.2018.05.018
DO - 10.1016/j.ahj.2018.05.018
M3 - Journal article
C2 - 30103092
VL - 204
SP - 128
EP - 138
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
ER -
ID: 218607491